The prognostic significance of serum XCL1 concentration in patients with acute lymphoblastic leukemia: a pilot study

There is no information about XCL1 in patients with acute lymphoblastic leukemia (ALL). The objective of this study was to correlate the serum levels of XCL1 and survival in ALL patients. Only ALL patients older than 12 months were considered to participate. Serum XCL1 was measured at diagnosis, end...

Full description

Saved in:
Bibliographic Details
Published in:Annals of hematology 2017-12, Vol.96 (12), p.2015-2024
Main Authors: Gutiérrez-Aguirre, Cesar Homero, Flores-Jiménez, Juan Antonio, Alatorre-Ricardo, Julio, Cantú-Rodríguez, Olga Graciela, Rosas-Taraco, Adrián, Salazar-Riojas, Rosario, Jaime-Pérez, José Carlos, Sánchez-Cárdenas, Mónica, López-Silva, Leslie, Martínez-Castilla, Azalia M., Salinas-Carmona, Mario Cesar, Gómez-Almaguer, David
Format: Article
Language:English
Subjects:
Adolescent
Adult
Aged
Chemokines, C - blood
Child
Child, Preschool
Disease-Free Survival
Hematology
Humans
Infant
Leukemia
Male
Medicine
Medicine & Public Health
Middle Aged
Neoplasm Proteins - blood
Oncology
Original Article
Pilot Projects
Precursor Cell Lymphoblastic Leukemia-Lymphoma - blood
Precursor Cell Lymphoblastic Leukemia-Lymphoma - drug therapy
Precursor Cell Lymphoblastic Leukemia-Lymphoma - mortality
Prospective Studies
Survival Rate
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:There is no information about XCL1 in patients with acute lymphoblastic leukemia (ALL). The objective of this study was to correlate the serum levels of XCL1 and survival in ALL patients. Only ALL patients older than 12 months were considered to participate. Serum XCL1 was measured at diagnosis, end of remission induction, and end of consolidation. Thirty-three ALL patients with median age of 21 years (1–78) were included. Higher XCL1 level (above 50 pg/mL) at ALL diagnosis correlated with higher survival ( p  = 0.038), whereas XCL1 level at end of induction and consolidation had no significant correlation. Concerning the behavior of serum XCL1 during treatment, higher survival at 5 years was observed in the group with progressively decreased levels of XCL1 (70%) than those with progressively increasing (29%) or no detectable XCL1 (14%). In conclusion, higher serum XCL1 levels at diagnosis and their progressive decline throughout chemotherapy could be correlated with higher survival.
ISSN:0939-5555
1432-0584
DOI:10.1007/s00277-017-3142-3